Alnylam Pharmaceuticals (NASDAQ:ALNY) PT Lowered to $196.00

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) had its price target lowered by analysts at JPMorgan Chase & Co. from $200.00 to $196.00 in a research report issued on Friday, Benzinga reports. The brokerage presently has a “neutral” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price objective points to a potential downside of 3.25% from the stock’s current price.

Several other analysts also recently weighed in on ALNY. EF Hutton Acquisition Co. I began coverage on Alnylam Pharmaceuticals in a research report on Tuesday, February 21st. They set a “buy” rating and a $304.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $415.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday. Chardan Capital reaffirmed a “buy” rating and set a $250.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, February 24th. Oppenheimer dropped their price objective on shares of Alnylam Pharmaceuticals from $256.00 to $249.00 and set an “outperform” rating for the company in a research note on Friday, February 24th. Finally, Morgan Stanley cut their target price on shares of Alnylam Pharmaceuticals from $210.00 to $205.00 and set an “equal weight” rating on the stock in a research report on Friday, February 24th. Seven investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $244.26.

Alnylam Pharmaceuticals Price Performance

ALNY stock opened at $202.58 on Friday. The company’s 50-day moving average price is $222.02 and its two-hundred day moving average price is $215.14. The firm has a market cap of $25.15 billion, a P/E ratio of -21.81 and a beta of 0.49. The company has a quick ratio of 3.34, a current ratio of 3.51 and a debt-to-equity ratio of 3.85. Alnylam Pharmaceuticals has a 12 month low of $117.58 and a 12 month high of $242.97.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) last posted its quarterly earnings results on Thursday, February 23rd. The biopharmaceutical company reported ($1.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.13) by $0.45. Alnylam Pharmaceuticals had a negative net margin of 109.04% and a negative return on equity of 1,287.80%. The business had revenue of $335.04 million for the quarter, compared to analyst estimates of $312.45 million. During the same quarter last year, the business posted ($2.16) EPS. The firm’s revenue for the quarter was up 29.6% on a year-over-year basis. On average, analysts anticipate that Alnylam Pharmaceuticals will post -6.78 earnings per share for the current fiscal year.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Indrani Lall Franchini sold 1,675 shares of the firm’s stock in a transaction that occurred on Thursday, February 2nd. The shares were sold at an average price of $226.01, for a total transaction of $378,566.75. Following the completion of the transaction, the executive vice president now owns 3,500 shares in the company, valued at approximately $791,035. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Belpointe Asset Management LLC acquired a new stake in Alnylam Pharmaceuticals during the 4th quarter worth about $25,000. Guardian Wealth Advisors LLC acquired a new stake in Alnylam Pharmaceuticals during the third quarter worth approximately $27,000. ANTIPODES PARTNERS Ltd bought a new stake in Alnylam Pharmaceuticals in the fourth quarter worth approximately $28,000. Allworth Financial LP lifted its stake in Alnylam Pharmaceuticals by 708.7% in the third quarter. Allworth Financial LP now owns 186 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 163 shares during the period. Finally, SeaCrest Wealth Management LLC bought a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter worth approximately $44,000.

About Alnylam Pharmaceuticals

(Get Rating)

Alnylam Pharmaceuticals, Inc is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Its products include ONPATTRO, GIVLAARI, and OXLUMO. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R.